¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"beta-adrenergic receptor blocking agent"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antimetabolic agent
    Ç×´ë»ç¹°Áú
  • antitumor agent
    Ç×¾ÏÁ¦
  • antiviral agent
    Ç×¹ÙÀÌ·¯½ºÁ¦, Ç×¹ÙÀÌ·¯½º¹°Áú
  • agent
    1. ¹°Áú 2. ÀÎÀÚ 3. -¾à, -Á¦
  • alkylating agent
    ¾Ëųȭ¾à¹°, ¾ËųȭÁ¦
  • anesthetic agent
    ¸¶ÃëÁ¦
  • biologic agent
    »ý¹°ÇÐÀûÁ¦Á¦
  • bacteriostatic agent
    Á¤±ÕÁ¦
  • bulking agent
    ÀåÈ®À强¾à¹°
  • compounding agent
    ¹èÇÕÁ¦, Á¶ÇÕÁ¦
  • contrast agent
    Á¶¿µÁ¦
  • carcinogenic agent
    ¹ß¾Ï¹°Áú
  • carcinostatic agent
    Á¦¾ÏÁ¦
  • cardioactive agent
    ½ÉÀåÀÛ¿ëÁ¦
  • cryoprotective agent
    µ¿ÇعæÁöÁ¦, ³Ãµ¿»óÇØ¹æÁöÁ¦
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antimetabolic agent
    Ç×´ë»ç¹°Áú
  • antitumor agent
    Ç×¾ÏÁ¦
  • etiologic agent
    ¿øÀÎü, º´ÀÎü
  • hyperosmotic agent
    °í»ïÅõ¾ÐÁ¦
  • induction agent
    À¯µµ¹°Áú
  • infectious agent
    °¨¿°Ã¼, °¨¿°¿ø
  • oxidizing agent
    »êÈ­Á¦
  • pressor agent
    ½Â¾ÐÁ¦, Ç÷¾Ð»ó½ÂÁ¦
  • sclerosing agent
    °æÈ­Á¦
  • tocolytic agent
    ÀڱüöÃà¾ïÁ¦Á¦
  • toxic agent
    µ¶¹°, µ¶±Ø¹°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • anorectic agent
    ½Ä¿å°¨ÅðÁ¦
  • anti-inflammatory agent
    Ç׿°ÁõÁ¦, ¼Ò¿°Á¦, ¿°Áõ¾à
  • antiallergic agent
    ¾Ë·¹¸£±â¾à
  • antiarrhythmic agent
    Ç׺ÎÁ¤¸ÆÁ¦
  • antiasthmatic agent
    (¢¡antasthmatic) Ç×õ½ÄÁ¦
  • antifoaming agent
    Ç×±âÆ÷Á¦, ±âÆ÷Á¦°ÅÁ¦
  • antifungal agent
    Ç×Áø±ÕÁ¦
  • antigen receptor
    Ç׿ø¼ö¿ëü
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • antimetabolic agent
    Ç×´ë»ç¹°Áú
  • antitumor agent
    Ç×¾ÏÁ¦
  • antiviral agent
    Ç×¹ÙÀÌ·¯½ºÁ¦, Ç×¹ÙÀÌ·¯½º¹°Áú
  • bacteriostatic agent
    Á¤±ÕÁ¦
  • biologic agent
    »ý¹°ÇÐÀûÁ¦Á¦
  • bulking agent
    ÀåÈ®À强¾à¹°
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Gustatory receptor
    ¹Ì°¢¼ö¿ëü(Ú«ÊÆâ¥é»ô÷)
  • H2 receptor antagonist
    H2 ¼ö¿ëü ±æÇ×Á¦µé
  • Ig receptor
    ¸é¿ª±Û·ÎºÒ¸° ¼ö¿ëü
  • Internalization, receptor
    ³»È­(Ò®ü§), ¼ö¿ëü(áôé»ô÷)
  • Kainate amino acid receptor
    Ä«À̳×ÀÌÆ® ¾Æ¹Ì³ë»ê ¼ö¿ëü(áôé»ô÷)
  • Kinesthetic receptor
    ¿îµ¿(ê¡ÔÑ)(°¨(Êï))°¢¼ö¿ëü(ÊÆáôé»ô÷)
  • NMDA receptor
    ¿£¾Úµð¿¡ÀÌ ¼ö¿ëü
  • T cell receptor
    T¼¼Æ÷[Ç׿ø]¼ö¿ëü
  • T cell receptor gene
    T¼¼Æ÷[Ç׿ø]¼ö¿ëü À¯ÀüÀÚ
  • acetylcholine receptor
    ¾Æ¼¼Æ¿Äݸ° ¼ö¿ëü(¼ö¿ë±â, °¨¼ö±â)
  • acetylcholine receptor
    ¾Æ¼¼Æ¿Äݸ°¼ö¿ëü
  • acetylcholine receptor antibody
    ¾Æ¼¼Æ¿Äݸ°¼ö¿ëüÇ×ü
  • acetylcholine receptor antibody assay
    ¾Æ¼¼Æ¿Äݸ°¼ö¿ëü Ç×Ã¼ÃøÁ¤
  • alpha-adrenal receptor antagonist
    ¾ËÆÄ ¾Æµå·¹³¯¸°¼ö¿ëüÂ÷´ÜÁ¦
  • alpha-adrenergic receptor
    ¾ËÆÄ-¾Æµå·¹³¯¸°¼ö¿ëü.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • beta receptor stimulating agent
    º£Å¸¼ö¿ëü ÀÚ±ØÁ¦( -áôé»ô÷ í©Ð½ð¥)
  • alpha blocking
    ¾ËÆÄÂ÷´Ü
  • antibody, blocking
    Â÷´ÜÇ×ü
  • blocking
    ¸·Èû, ´ÜÀý, Â÷´Ü.
  • blocking antibody
    Â÷´ÜÇ×ü(ó´Ó¨ù÷ô÷)
  • blocking antibody =blocker
    Â÷´ÜÇ×ü(¡­ù÷ô÷).
  • blocking of thought
    »ç°íÀÇ ¸·Èû
  • blocking test
    Â÷´Ü½ÃÇè(ó´Ó¨ãËúÐ).
  • calcium channel blocker ; calcium channel blocking drug
    Ä®½·Åë·ÎºÀ¼â¾à ¹°<Á¦>, Ä®½·Åë·Î Â÷´Ü¾à¹°<Á¦>.
  • calcium channel blocker ; calcium channel blocking drug
    Ä®½·Åë·ÎºÀ¼â¾à¹°<Á¦>, Ä®½·Åë·ÎÂ÷´Ü¾à¹°<Á¦>.
  • depolarizing neuromuscular blocking drug
    Å»ºÐ±Ø¼º ½Å°æ±ÙºÀ¼â¾à¹°.
  • ganglionic blocking action
    ½Å°æÀýÂ÷´ÜÀÛ¿ë.
  • genetic blocking
    À¯ÀüÀû Â÷´Ü(ë¶îîîÜó´Ó¨).
  • genetic blocking
    À¯ÀüÀû Â÷´Ü.
  • minimum blocking concentration
    ÃÖ¼ÒÂ÷´Ü³óµµ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • LDL receptor
    LDL ¼ö¿ëü(áôé»ô÷)
  • ligand-receptor internalization
    ¸®°£µå-¼ö¿ëü(áôé»ô÷) ³»ÀÔ(Ò®ìý)
  • mineralocorticoid receptor
    ±¤Áú(ÎÎòõ) ÄÚ¸£Æ¼ÄÚÀÌµå ¼ö¿ëü(áôé»ô÷)
  • mobile receptor model
    À̵¿¼ö¿ëü(ì¹ÔÑáôé»ô÷) ¸ðµ¨
  • muscarinic receptor
    ¹«½ºÄ«¸°¼ö¿ëü(áôéÄô÷)
  • nicotinic receptor
    ´ÏÄÚÆ¾¼ö¿ëü(â¥é»ô÷)
  • opiate receptor
    ¾ÆÆíÁ¦(ð¥) ¼ö¿ëü(áôé»ô÷)
  • opioid receptor
    ¾ÆÆí°è(ͧ) ¾à¹°¼ö¿ëü(å·Úªáôé»ô÷)
  • receptor
    ¼ö¿ëü(áôé»ô÷)
  • receptor destroying enzyme
    ¼ö¿ëü ÆÄ±«È¿¼Ò(áôé»ô÷÷òÎÕý£áÈ)
  • receptor down regulation
    ¼ö¿ëü ÇÏÇâ Á¶Àý(áôé»ô÷ù»ú¾ðàï½)
  • receptor element
    ¼ö¿ëü Á¶Àý ¿ä¼Ò(áôé»ô÷ðàï½é©áÈ)
  • receptor gradient
    ¼ö¿ëü ±¸¹è(áôé»ô÷ÎþÛÕ)
  • receptor internalization
    ¼ö¿ëü ³»ÀÔ(áôé»ô÷Ò®ìý)
  • receptor-mediated endocytosis
    ¼ö¿ëü¸Å°³ ¼¼Æ÷³» ÀÌÀÔ(áôé»ô÷ØÚË¿á¬øàÒ®ì¹ìý)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • protective agent
    º¸È£¾à, ÇÇÆ÷¾à
  • radioopaque agent
    ¹æ»ç¼±ºñÅõ°ú¼ºÁ¦Àç
  • radioprotective agent
    ¹æ»ç¼±¹æÈ£Á¦
  • sclerosing agent
    °æÈ­¾à
  • therapeutic agent
    Ä¡·á¾à
  • thrombolytic agent
    Ç÷Àü¿ëÇØ¾à
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
BA Bachelor of Arts; backache; bacterial agglutination; basilar artery; basion; benzyladenine; best amp...
ER efficiency ratio; epigastric region; ejection rate; electroresection; emergency room; endoplasmic re...
RAR rapidly adapting receptor; rat insulin receptor; retinoic acid receptor; right arm reclining; right ...
CR calculation rate; calculus removed; calorie-restricted; cardiac rehabilitation; cardiac resuscitatio...
CRL cell repository line; Certified Record Librarian; complement receptor location; complement receptor ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
NMB neuromuscular blocking
a Agent
CAA Chicken anaemia agent
FWA fluorescent whitening agent
SMA Snow Mountain Agent
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • A1 receptor
    A1 ¼ö¿ëü, A1 ¼ö¿ë±â, A1 °¨¼ö±â
  • acetylcholine receptor
    ¾Æ¼¼Æ¿Äݸ° ¼ö¿ëü
  • alpha-adrenergic receptor
    ¾ËÆÄ-¾Æµå·¹³¯¸° ¼ö¿ëü
  • antigen receptor
    Ç׿ø ¼ö¿ëü
  • beta receptor blocker
    º£Å¸ ¼ö¿ëü Â÷´ÜÁ¦
  • C3 receptor
    C3 ¼ö¿ëü
    Ç÷¾× ¼ÓÀÇ ¿©·¯ ¼¼Æ÷¿¡´Â º¸Ã¼ Á¦ 3¼ººÐ¿¡ ´ëÇÑ ¼ö¿ëü¸¦ °¡Áö°í ÀÖ´Â °ÍÀÌ ÀÖ´Ù. B ¸²ÇÁ±¸´Â C3b ¹× C3dÀÇ ¼ö¿ëü¸¦ °¡Áö°í ÀÖ´Ù. T ¸²ÇÁ±¸´Â C3b ¼ö¿ëü´Â À̹ۿ¡ È£Áß±¸, macro
  • deep receptor
    ½ÉºÎ ¼ö¿ëü
  • distance receptor
    °Å¸® ¼ö¿ë±â
  • dominant receptor
    ¿ì¼º ¼ö¿ëü
  • dopamine receptor
    µµÆÄ¹Î ¼ö¿ëü
  • down-regulation of receptor
    ¼ö¿ëü ÇÏÇâ Á¶Àý
  • drug receptor
    ¾à¹° ¼ö¿ëü
  • estrogen receptor protein
    ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ´Ü¹éÁú
  • Fc receptor
    Fc ¼ö¿ëü
    Ç×üÀÇ Fc ºÐÀý°ú °áÇÕÇÏ´Â ¼¼Æ÷ Ç¥¸é ¼ö¿ëüÀ̸ç B ¼¼Æ÷, macro
  • free receptor
    À¯¸® ¼ö¿ëü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
spermatogenesis-blocking agents Chemical substances which inhibit the process of spermatozoa formation at either the first stage, in which spermatogonia develop into spermatocytes and then into spermatids, or the second stage, in which spermatids transform into spermatozoa.
(12 Dec 1998)
neuromuscular blocking agents Drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. They can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarising agents) or noncompetitive, depolarising agents (neuromuscular depolarising agents). Both prevent acetylcholine from triggering the muscle contraction and they are used as anaesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.
(12 Dec 1998)
agent <pharmacology> Any power, principle or substance capable of producing an effect, whether physical, chemical or biological.
Origin: L. Agens = acting
(18 Nov 1997)
agent, antihypertensive As the name suggests, a drug aimed at reducing high blood pressure (hypertension).
(12 Dec 1998)
agent, anti-infective Something capable of acting against infection, by inhibiting the spread of an infectious agent or by killing the infectious agent outright.
(12 Dec 1998)
Agent Orange An herbicide and defoliant, consisting of (2,4,5-trichlorophenoxy)acetic acid, (2,4-dichlorophenoxy)acetic acid, and dioxin, that was widely used in the Vietnam War; it has been shown to possess residual post-exposure carcinogenic and teratogenic properties in humans.
(05 Mar 2000)
agent, tocolytic A medication that can inhibit labour, slow down or halt the contractions of the uterus. Tocolytic agents are widely used today to treat premature labour and permit pregnancy to procede and so let the foetus gain in size and maturity before being born.
(12 Dec 1998)
alkylating agent <oncology, pharmacology> A reagent that places an alkyl group, for example propyl in place of a nucleophilic group in a molecule. Alkylating reagents include a number of cytotoxic drugs some of which react fairly specifically with N7 of the purine ring and lead to depurination of DNA, for example the agent ethyl ethanesulphonic acid and thus to mutagenesis. The drugs interaction with DNAand prevents the division of the cells.
Examples of drugs include: busulphan, chlorambucil, cyclophosphamide, melphalan.
(29 Sep 1997)
antianxiety agent A functional category of drugs useful in the treatment of anxiety and able to reduce anxiety at doses which do not cause excessive sedation (e.g., diazepam).
Synonym: anxiolytic, minor tranquilliser.
(05 Mar 2000)
antidiabetic agent A substance that helps a person with diabetes control the level of glucose (sugar) in the blood so that the body works as it should. See: insulin.
(09 Oct 1997)
antifibrinolytic agent Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive haemorrhage and in other coagulation disorders.
(12 Dec 1998)
antifoam agent A chemical that reduces the surface tension of foams that form on thesurface of broths in fermentors because of aeration or agitation. Stearyldecanol, octal decanol, vegetable oils, silicones, sulphonates, andpolypropylene glycol are typically used, though they can cause problems inrefining the broth later on.
(09 Oct 1997)
anti-inflammatory agent Agents that counteract or suppress the inflammatory process. An antirheumatic agent or inflammation mediator, both endogenous and exogenous substances used to counteract the inflammatory process or alleviate or prevent rheumatic diseases, and the compounds that mediate the inflammation process.
(12 Dec 1998)
anti-inflammatory agent, non-steroidal Anti-inflammatory agents that are not steroids. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They are used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Certain nsaids also may inhibit lipoxygenase enzymes or phospholipase c or may modulate T-cell function. (ama drug evaluations annual, 1994, p 1814-5)
(12 Dec 1998)
anti-inflammatory agent, steroidal Steroidal agents capable of suppressing or counteracting the inflammatory process by acting on body mechanisms, without directly antagonizing the causative agents.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • double agent
    ÀÌÁß °£Ã¸
  • estate agent
    ºÎµ¿»ê°ü¸®ÀÎ;Áß°³¾÷ÀÚ
  • fiscal agent
    À繫 ´ë¸® ±â°ü;À繫 ´ë¸®ÀÎ
  • forwarding agent
    ¿î¼Û¾÷ÀÚ
  • free agent
    ÀÚÁÖÀûÀÎ ÇàÀ§ÀÚ;ÀÚÀ¯°è¾à ¼±¼ö )
  • general agent
    ÃѴ븮ÀÎ
  • house agent
    º¹´ö¹æ;°¡¿Á ¸Å¸Å ¼Ò°³¾÷ÀÚ
  • inquiry agent
    (¿µ)»ç½Ç ŽÁ¤
  • insurance agent
    º¸Çè´ë¸®Á¡
  • land agent
    ÅäÁö ¸Å¸Å Áß°³¾÷ÀÚ;ÅäÁö °ü¸®ÀÎ
  • nerve agent
    (±º¿ëÀÇ)½Å°æ°è¿¡ ÀÛ¿ëÇÏ´Â ¹°Áú;½Å°æ°¡½º(µî)
  • parliamentary agent
    Á¤´çÀÇ ÀÇȸ ´ëº¯ÀÎ
  • press agent
    º¸µµ¿ø;¼±Àü¿ø
  • publicity agent
    ±¤°í ´ë¸®¾÷ÀÚ
  • purchasing agent
    ±¸¸Å ´ã´ç
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á